Product image of Methylprednisolon Acis (Methylprednisolone Sodium Succinate) supplied by GNH India

Methylprednisolon Acis

Active Ingredient:
Methylprednisolone Sodium Succinate
Origin:
EU

Methylprednisolon Acis (Methylprednisolone Sodium Succinate)

Methylprednisolone sodium succinate, the active ingredient in Methylprednisolon Acis, is a glucocorticoid presented as an injectable solution for intramuscular and intravenous use. It is employed to treat severe allergic reactions, asthma exacerbations, rheumatoid arthritis, multiple sclerosis relapses, acute inflammation and other autoimmune disorders.

GNH India supplies Methylprednisolon Acis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and reliable cold‑chain logistics for injectable products.

Manufacturer / TM Owner

Acis Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylprednisolone sodium succinate is a glucocorticoid used to manage inflammatory and immune‑mediated conditions.

  • Severe allergic reactions: rapid reduction of airway swelling and systemic inflammation.
  • Asthma exacerbations: improves breathing by decreasing airway edema and hyperresponsiveness.
  • Rheumatoid arthritis: alleviates joint pain and swelling during acute flares.
  • Multiple sclerosis relapses: shortens duration of neurologic deficits by suppressing inflammation.
  • Acute inflammation: controls severe tissue inflammation when oral therapy is insufficient.

How It Works

  • Methylprednisolone sodium succinate diffuses into cells and binds cytosolic glucocorticoid receptors, forming a complex that translocates to the nucleus. The complex interacts with glucocorticoid response elements on DNA, up‑regulating anti‑inflammatory proteins and down‑regulating pro‑inflammatory cytokines, chemokines and adhesion molecules, thereby suppressing immune cell activation and reducing vascular permeability.

Side Effects

Methylprednisolone sodium succinate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Increased blood glucose: transient hyperglycemia, especially in diabetic patients.
  • Fluid retention: mild edema or weight gain.
  • Mood changes: irritability, anxiety or insomnia.
  • Gastrointestinal discomfort: nausea or dyspepsia.

Serious or Rare Side Effects

  • Severe infection: heightened risk due to immunosuppression.
  • Adrenal suppression: possible cortisol deficiency after abrupt discontinuation.
  • Osteoporosis: bone loss with prolonged therapy.
  • Psychiatric disturbances: psychosis or severe depression.

Precautions & Warnings

Before initiating therapy with Methylpredolon Acis, clinicians should consider several precautionary measures.

  • Assess infection risk: evaluate for active or latent infections before use.
  • Monitor glucose: check blood sugar levels in diabetic or pre‑diabetic patients.
  • Screen bone health: consider baseline bone density in long‑term therapy candidates.
  • Evaluate pregnancy: use only when benefit outweighs risk, as category C.
  • Review concomitant drugs: avoid combining with strong CYP3A4 inhibitors without adjustment.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methylprednisolone sodium succinate can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase steroid exposure and toxicity.
  • Live vaccines: risk of uncontrolled infection due to immunosuppression.
  • Anticoagulants (warfarin): enhanced anticoagulant effect, requiring INR monitoring.
  • NSAIDs: increased risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

  • Diabetic agents: possible need for dose adjustment due to hyperglycemia.
  • Antihypertensives: steroid‑induced fluid retention may blunt blood pressure control.
  • Antifungals (e.g., fluconazole): may modestly raise steroid levels.
  • Non‑live vaccines: monitor immune response.

Frequently Asked Questions

Methylprednisolon Acis contains methylprednisolone sodium succinate, a glucocorticoid indicated for severe allergic reactions, asthma exacerbations, rheumatoid arthritis flares, multiple sclerosis relapses, acute inflammatory episodes and other autoimmune disorders where rapid anti‑inflammatory control is required.

Methylprednisolone binds to intracellular glucocorticoid receptors, and the resulting complex moves into the nucleus where it modulates gene transcription. This up‑regulates anti‑inflammatory proteins and down‑regulates pro‑inflammatory cytokines, chemokines and adhesion molecules, producing potent anti‑inflammatory and immunosuppressive effects.

The appropriate dose of Methylprednisolon Acis is determined by the prescribing clinician based on the specific indication, severity of the condition, patient weight, renal and hepatic function, and any concomitant therapies. No fixed dosing regimen is provided in product literature.

Methylprednisolon Acis is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential fetal risk. Limited data are available for breastfeeding; caution is advised and a risk‑benefit assessment should be performed.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Methylprednisolon Acis is a parenteral glucocorticoid with higher anti‑inflammatory potency than prednisone on a milligram‑per‑milligram basis and a shorter duration of action than dexamethasone. Its rapid onset makes it suitable for acute severe episodes, whereas oral corticosteroids are often preferred for chronic maintenance.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain sterility and potency.

Methylpredisolon Acis is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional using aseptic technique, with the dose and route selected by the prescriber according to the clinical situation.

Serious risks include severe infections due to immunosuppression, adrenal insufficiency after abrupt discontinuation, significant hyperglycemia, osteoporosis with long‑term use, and psychiatric effects such as psychosis or severe depression. Patients should be monitored closely for these events.

Methylpredisolon Acis is contraindicated in patients with known hypersensitivity to methylprednisolone or any component of the formulation, and in those with systemic fungal infections. Caution is also advised for patients with uncontrolled diabetes, active tuberculosis, or severe hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylprednisolone Sodium Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT